Next Article in Journal
A Randomized, Double-Blind, Placebo-Controlled Investigation of Selenium Supplementation in Women at Elevated Risk for Breast Cancer: Lessons for Re-Emergent Interest in Selenium and Cancer
Next Article in Special Issue
Onset of Action of Selected Second-Generation Antipsychotics (Pines)–A Systematic Review and Meta-Analyses
Previous Article in Journal
Untargeted Lipidomics Reveals Characteristic Biomarkers in Patients with Ankylosing Spondylitis Disease
Previous Article in Special Issue
The Use of Second-Generation Antipsychotics in Patients with Severe Schizophrenia in the Real World: The Role of the Route of Administration and Dosage—A 5-Year Follow-Up
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 11
Issue 1
10.3390/biomedicines11010048
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Glucose and Lipid Profiles Predict Anthropometric Changes in Drug-Naïve Adolescents Starting Treatment with Risperidone or Sertraline: A Pilot Study

by
Emilia Matera
1,*,
Gloria Cristofano
2,
Flora Furente
2,
Lucia Marzulli
2,
Martina Tarantini
2,
Lucia Margari
1,
Francesco Maria Piarulli
2,
Andrea De Giacomo
2 and
Maria Giuseppina Petruzzelli
2
1
DiMePRe-J—Department of Precision and Rigenerative Medicine—Jonic Area, University of Bari “Aldo Moro”, 70100 Bari, Italy
2
DiBraiN—Department of Translational Biomedicine Neurosciences, University of Bari “Aldo Moro”, 70100 Bari, Italy
*
Author to whom correspondence should be addressed.
Biomedicines 2023, 11(1), 48; https://doi.org/10.3390/biomedicines11010048
Submission received: 31 October 2022 / Revised: 15 December 2022 / Accepted: 20 December 2022 / Published: 25 December 2022
(This article belongs to the Special Issue Antipsychotics: 70 Years)
Review Reports Versions Notes

Abstract

Psychiatric disorders are associated with cardiometabolic diseases, partly due to adverse drug effects with individual risk variabilities. Risperidone and sertraline are widely used for youths. Although they may be exposed to anthropometric changes, few data about this population exist. We evaluated the correlation between several blood parameters and body changes in a very small group of drug-naïve adolescents who had started risperidone or sertraline. We examined weight, waist circumference (WC), WC/height ratio and body mass index (BMI) at baseline (T0) and after at least three months of therapy (T1), and blood glucose and lipid profiles at T0. Here, we show significant increases in several anthropometric parameters in both groups, a negative correlation between HDL and ΔWC in the risperidone group and positive correlations between insulin and ΔBMI and between HOMA-IR and ΔBMI in the sertraline group. Despite the sample size, these results are important because it is difficult to study adolescents who are long-term-compliant with psychotropic drugs. This pilot study supports the importance of future large-scale investigations to understand the metabolic risk profiles of psychotropic drugs, their individual vulnerabilities and their underlying mechanisms. Simultaneous guideline-based psychiatric and metabolic interventions should be part of daily practice.
Keywords: second-generation antipsychotics; risperidone; sertraline; selective serotonin reuptake inhibitors; metabolic risk; anthropometric changes; glucose profile; lipid profile; weight gain; drug-naïve adolescents second-generation antipsychotics; risperidone; sertraline; selective serotonin reuptake inhibitors; metabolic risk; anthropometric changes; glucose profile; lipid profile; weight gain; drug-naïve adolescents

Share and Cite

MDPI and ACS Style

Matera, E.; Cristofano, G.; Furente, F.; Marzulli, L.; Tarantini, M.; Margari, L.; Piarulli, F.M.; De Giacomo, A.; Petruzzelli, M.G. Glucose and Lipid Profiles Predict Anthropometric Changes in Drug-Naïve Adolescents Starting Treatment with Risperidone or Sertraline: A Pilot Study. Biomedicines 2023, 11, 48. https://doi.org/10.3390/biomedicines11010048

AMA Style

Matera E, Cristofano G, Furente F, Marzulli L, Tarantini M, Margari L, Piarulli FM, De Giacomo A, Petruzzelli MG. Glucose and Lipid Profiles Predict Anthropometric Changes in Drug-Naïve Adolescents Starting Treatment with Risperidone or Sertraline: A Pilot Study. Biomedicines. 2023; 11(1):48. https://doi.org/10.3390/biomedicines11010048

Chicago/Turabian Style

Matera, Emilia, Gloria Cristofano, Flora Furente, Lucia Marzulli, Martina Tarantini, Lucia Margari, Francesco Maria Piarulli, Andrea De Giacomo, and Maria Giuseppina Petruzzelli. 2023. "Glucose and Lipid Profiles Predict Anthropometric Changes in Drug-Naïve Adolescents Starting Treatment with Risperidone or Sertraline: A Pilot Study" Biomedicines 11, no. 1: 48. https://doi.org/10.3390/biomedicines11010048

APA Style

Matera, E., Cristofano, G., Furente, F., Marzulli, L., Tarantini, M., Margari, L., Piarulli, F. M., De Giacomo, A., & Petruzzelli, M. G. (2023). Glucose and Lipid Profiles Predict Anthropometric Changes in Drug-Naïve Adolescents Starting Treatment with Risperidone or Sertraline: A Pilot Study. Biomedicines, 11(1), 48. https://doi.org/10.3390/biomedicines11010048

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop